Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM) -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (131)	2/4/2000 11:42:00 PM
From: Carl R.	Read Replies (1) \| Respond to of 207

Hank, I now have a cold that isn't responding to Zicam, after successfully treating 3 other ones. Based solely on my personal experience I would say that Zicam either works extremely fast (1 1/2 days), or not at all. As for the unpleasantness, it isn't pleasant, but neither is having a cold. I agree that after the lozenges many people would avoid this product at first, at least until hearing success stories from others. As for the other "fast-acting" remedies, they may be fast acting, but they just treat the symptoms. I think you miss the greater question which is "How will repeat purchases be affected by inconsistent results?" Will they behave like rats who repeatedly respond to random reinforcement and simply increase the rate of usage of Zicam? Or will they get frustrated with the product and go back to decongestants that, while they don't cure the problem, at least provide predictable response? Myself, I responded by increasing the rate of application to every 2 hours, but now after 2 1/2 days it is becoming clear it doesn't work on this variety of cold. Since I understand the science (sort of), I will stop using it on this cold, and save it for the next one. What would others do? Carl

To: Hank who wrote (131)	2/5/2000 12:16:00 AM
From: Mad2	Respond to of 207

Hank, I'm not so concerned about next cold season. Stocks react to the next quarter. Zicam advertized at 9pm on a network station in Chicago. Gumm is trying to keep momentum going with the advertizing, however they do face costs not incured in the last quarter. I'd like a handle on 1st qtr "00" revenues........Net income will be secondary.......GUMM's doing what they can to create sequential revenue growth as that's what will drive the stock price.....if the revenues don't materialize then GUMM takes a big haircut....as their branding effort will add to the cost line. Mad2